TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes

Pancreatic ductal adenocarcinoma (PDAC) is characterized by advanced disease stage at presentation, aggressive disease biology, and resistance to therapy, resulting in an extremely poor 5-year survival rate of <10%. PDAC is classified into transcriptional subtypes with distinct survival character...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gastroenterology (New York, N.Y. 1943) Ročník 161; číslo 2; s. 653
Hlavní autoři: Eyres, Michael, Lanfredini, Simone, Xu, Haonan, Burns, Adam, Blake, Andrew, Willenbrock, Frances, Goldin, Robert, Hughes, Daniel, Hughes, Sophie, Thapa, Asmita, Vavoulis, Dimitris, Hubert, Aline, D'Costa, Zenobia, Sabbagh, Ahmad, Abraham, Aswin G, Blancher, Christine, Jones, Stephanie, Verrill, Clare, Silva, Michael, Soonawalla, Zahir, Maughan, Timothy, Schuh, Anna, Mukherjee, Somnath, O'Neill, Eric
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.08.2021
Témata:
ISSN:1528-0012, 1528-0012
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by advanced disease stage at presentation, aggressive disease biology, and resistance to therapy, resulting in an extremely poor 5-year survival rate of <10%. PDAC is classified into transcriptional subtypes with distinct survival characteristics, although how these arise is not known. Epigenetic deregulation, rather than genetics, has been proposed to underpin progression, but exactly why is unclear and is hindered by the technical limitations of analyzing clinical samples. We performed genome-wide epigenetic mapping of DNA modifications 5-methylcytosine and 5-hydroxymethylcytosine (5hmc) using oxidative bisulfite sequencing from formalin-embedded sections. We identified overlap with transcriptional signatures in formalin-fixed, paraffin-embedded tissue from resected patients, via bioinformatics using iCluster and mutational profiling and confirmed them in vivo. We found that aggressive squamous-like PDAC subtypes result from epigenetic inactivation of loci, including GATA6, which promote differentiated classical pancreatic subtypes. We showed that squamous-like PDAC transcriptional subtypes are associated with greater loss of 5hmc due to reduced expression of the 5-methylcytosine hydroxylase TET2. Furthermore, we found that SMAD4 directly supports TET2 levels in classical pancreatic tumors, and loss of SMAD4 expression was associated with reduced 5hmc, GATA6, and squamous-like tumors. Importantly, enhancing TET2 stability using metformin and vitamin C/ascorbic acid restores 5hmc and GATA6 levels, reverting squamous-like tumor phenotypes and WNT-dependence in vitro and in vivo. We identified epigenetic deregulation of pancreatic differentiation as an underpinning event behind the emergence of transcriptomic subtypes in PDAC. Our data showed that restoring epigenetic control increases biomarkers of classical pancreatic tumors that are associated with improved therapeutic responses and survival.
AbstractList Pancreatic ductal adenocarcinoma (PDAC) is characterized by advanced disease stage at presentation, aggressive disease biology, and resistance to therapy, resulting in an extremely poor 5-year survival rate of <10%. PDAC is classified into transcriptional subtypes with distinct survival characteristics, although how these arise is not known. Epigenetic deregulation, rather than genetics, has been proposed to underpin progression, but exactly why is unclear and is hindered by the technical limitations of analyzing clinical samples. We performed genome-wide epigenetic mapping of DNA modifications 5-methylcytosine and 5-hydroxymethylcytosine (5hmc) using oxidative bisulfite sequencing from formalin-embedded sections. We identified overlap with transcriptional signatures in formalin-fixed, paraffin-embedded tissue from resected patients, via bioinformatics using iCluster and mutational profiling and confirmed them in vivo. We found that aggressive squamous-like PDAC subtypes result from epigenetic inactivation of loci, including GATA6, which promote differentiated classical pancreatic subtypes. We showed that squamous-like PDAC transcriptional subtypes are associated with greater loss of 5hmc due to reduced expression of the 5-methylcytosine hydroxylase TET2. Furthermore, we found that SMAD4 directly supports TET2 levels in classical pancreatic tumors, and loss of SMAD4 expression was associated with reduced 5hmc, GATA6, and squamous-like tumors. Importantly, enhancing TET2 stability using metformin and vitamin C/ascorbic acid restores 5hmc and GATA6 levels, reverting squamous-like tumor phenotypes and WNT-dependence in vitro and in vivo. We identified epigenetic deregulation of pancreatic differentiation as an underpinning event behind the emergence of transcriptomic subtypes in PDAC. Our data showed that restoring epigenetic control increases biomarkers of classical pancreatic tumors that are associated with improved therapeutic responses and survival.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by advanced disease stage at presentation, aggressive disease biology, and resistance to therapy, resulting in an extremely poor 5-year survival rate of <10%. PDAC is classified into transcriptional subtypes with distinct survival characteristics, although how these arise is not known. Epigenetic deregulation, rather than genetics, has been proposed to underpin progression, but exactly why is unclear and is hindered by the technical limitations of analyzing clinical samples.BACKGROUND & AIMSPancreatic ductal adenocarcinoma (PDAC) is characterized by advanced disease stage at presentation, aggressive disease biology, and resistance to therapy, resulting in an extremely poor 5-year survival rate of <10%. PDAC is classified into transcriptional subtypes with distinct survival characteristics, although how these arise is not known. Epigenetic deregulation, rather than genetics, has been proposed to underpin progression, but exactly why is unclear and is hindered by the technical limitations of analyzing clinical samples.We performed genome-wide epigenetic mapping of DNA modifications 5-methylcytosine and 5-hydroxymethylcytosine (5hmc) using oxidative bisulfite sequencing from formalin-embedded sections. We identified overlap with transcriptional signatures in formalin-fixed, paraffin-embedded tissue from resected patients, via bioinformatics using iCluster and mutational profiling and confirmed them in vivo.METHODSWe performed genome-wide epigenetic mapping of DNA modifications 5-methylcytosine and 5-hydroxymethylcytosine (5hmc) using oxidative bisulfite sequencing from formalin-embedded sections. We identified overlap with transcriptional signatures in formalin-fixed, paraffin-embedded tissue from resected patients, via bioinformatics using iCluster and mutational profiling and confirmed them in vivo.We found that aggressive squamous-like PDAC subtypes result from epigenetic inactivation of loci, including GATA6, which promote differentiated classical pancreatic subtypes. We showed that squamous-like PDAC transcriptional subtypes are associated with greater loss of 5hmc due to reduced expression of the 5-methylcytosine hydroxylase TET2. Furthermore, we found that SMAD4 directly supports TET2 levels in classical pancreatic tumors, and loss of SMAD4 expression was associated with reduced 5hmc, GATA6, and squamous-like tumors. Importantly, enhancing TET2 stability using metformin and vitamin C/ascorbic acid restores 5hmc and GATA6 levels, reverting squamous-like tumor phenotypes and WNT-dependence in vitro and in vivo.RESULTSWe found that aggressive squamous-like PDAC subtypes result from epigenetic inactivation of loci, including GATA6, which promote differentiated classical pancreatic subtypes. We showed that squamous-like PDAC transcriptional subtypes are associated with greater loss of 5hmc due to reduced expression of the 5-methylcytosine hydroxylase TET2. Furthermore, we found that SMAD4 directly supports TET2 levels in classical pancreatic tumors, and loss of SMAD4 expression was associated with reduced 5hmc, GATA6, and squamous-like tumors. Importantly, enhancing TET2 stability using metformin and vitamin C/ascorbic acid restores 5hmc and GATA6 levels, reverting squamous-like tumor phenotypes and WNT-dependence in vitro and in vivo.We identified epigenetic deregulation of pancreatic differentiation as an underpinning event behind the emergence of transcriptomic subtypes in PDAC. Our data showed that restoring epigenetic control increases biomarkers of classical pancreatic tumors that are associated with improved therapeutic responses and survival.CONCLUSIONSWe identified epigenetic deregulation of pancreatic differentiation as an underpinning event behind the emergence of transcriptomic subtypes in PDAC. Our data showed that restoring epigenetic control increases biomarkers of classical pancreatic tumors that are associated with improved therapeutic responses and survival.
Author Burns, Adam
Thapa, Asmita
Blake, Andrew
Hughes, Daniel
Blancher, Christine
Eyres, Michael
Sabbagh, Ahmad
Maughan, Timothy
Lanfredini, Simone
Vavoulis, Dimitris
O'Neill, Eric
Hubert, Aline
Mukherjee, Somnath
Hughes, Sophie
Verrill, Clare
Goldin, Robert
Jones, Stephanie
D'Costa, Zenobia
Abraham, Aswin G
Soonawalla, Zahir
Willenbrock, Frances
Silva, Michael
Schuh, Anna
Xu, Haonan
Author_xml – sequence: 1
  givenname: Michael
  surname: Eyres
  fullname: Eyres, Michael
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 2
  givenname: Simone
  surname: Lanfredini
  fullname: Lanfredini, Simone
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 3
  givenname: Haonan
  surname: Xu
  fullname: Xu, Haonan
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 4
  givenname: Adam
  surname: Burns
  fullname: Burns, Adam
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 5
  givenname: Andrew
  surname: Blake
  fullname: Blake, Andrew
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 6
  givenname: Frances
  surname: Willenbrock
  fullname: Willenbrock, Frances
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 7
  givenname: Robert
  surname: Goldin
  fullname: Goldin, Robert
  organization: Centre for Pathology, Imperial College, London, United Kingdom
– sequence: 8
  givenname: Daniel
  surname: Hughes
  fullname: Hughes, Daniel
  organization: Department of Oncology, University of Oxford, Oxford, UK; Department of Hepatobiliary and Pancreatic Surgery, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom
– sequence: 9
  givenname: Sophie
  surname: Hughes
  fullname: Hughes, Sophie
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 10
  givenname: Asmita
  surname: Thapa
  fullname: Thapa, Asmita
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 11
  givenname: Dimitris
  surname: Vavoulis
  fullname: Vavoulis, Dimitris
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 12
  givenname: Aline
  surname: Hubert
  fullname: Hubert, Aline
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 13
  givenname: Zenobia
  surname: D'Costa
  fullname: D'Costa, Zenobia
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 14
  givenname: Ahmad
  surname: Sabbagh
  fullname: Sabbagh, Ahmad
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 15
  givenname: Aswin G
  surname: Abraham
  fullname: Abraham, Aswin G
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 16
  givenname: Christine
  surname: Blancher
  fullname: Blancher, Christine
  organization: Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
– sequence: 17
  givenname: Stephanie
  surname: Jones
  fullname: Jones, Stephanie
  organization: Oxford Radcliffe Biobank, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom
– sequence: 18
  givenname: Clare
  surname: Verrill
  fullname: Verrill, Clare
  organization: Nuffield Department of Surgical Sciences and Oxford National Institute for Health Research Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
– sequence: 19
  givenname: Michael
  surname: Silva
  fullname: Silva, Michael
  organization: Department of Hepatobiliary and Pancreatic Surgery, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom
– sequence: 20
  givenname: Zahir
  surname: Soonawalla
  fullname: Soonawalla, Zahir
  organization: Department of Hepatobiliary and Pancreatic Surgery, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom
– sequence: 21
  givenname: Timothy
  surname: Maughan
  fullname: Maughan, Timothy
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 22
  givenname: Anna
  surname: Schuh
  fullname: Schuh, Anna
  organization: Department of Oncology, University of Oxford, Oxford, UK
– sequence: 23
  givenname: Somnath
  surname: Mukherjee
  fullname: Mukherjee, Somnath
  email: somnath.mukherjee@ouh.nhs.uk
  organization: Department of Oncology, University of Oxford, Oxford, UK. Electronic address: somnath.mukherjee@ouh.nhs.uk
– sequence: 24
  givenname: Eric
  surname: O'Neill
  fullname: O'Neill, Eric
  email: eric.oneill@oncology.ox.ac.uk
  organization: Department of Oncology, University of Oxford, Oxford, UK. Electronic address: eric.oneill@oncology.ox.ac.uk
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33915173$$D View this record in MEDLINE/PubMed
BookMark eNpNUF1LwzAUDTJxH_oPRPLoS2c-2-axbHMKEwXrc0nTZGa2aU3awf69BScIF-7h3HMOnDsHE9c6DcAtRkuMOH04LPcy9L5dEkTwErFx2AWYYU7SCCFMJv_wFMxDOCCEBE3xFZhSKjDHCZ2BY77JCVx7e9QB8s9GwRfpv6zbw9bAbZZnMZSugpvO7rXTvVWyrk9wrY11o-FNOuW1HGm4HlQva5hV2rVKemVd20iYe-mC8rbrbevG8_tQ9qdOh2twaWQd9M15L8DH4yZfPUW71-3zKttFipOkjyojDEaGpSrmOmXSpFwZFCsRC65KhnhMS8SlSOlYjXChhEAqSRRhJRUMVWQB7n9zO99-Dzr0RWOD0nUtnW6HUBBOUJoQysgovTtLh7LRVdF520h_Kv5-RX4AKYNuow
CitedBy_id crossref_primary_10_1038_s41392_023_01537_x
crossref_primary_10_4251_wjgo_v15_i9_1505
crossref_primary_10_1016_j_devcel_2025_07_002
crossref_primary_10_3389_fcell_2021_748631
crossref_primary_10_1016_j_pan_2022_08_007
crossref_primary_10_3390_cells11192939
crossref_primary_10_1016_j_canlet_2025_217911
crossref_primary_10_3390_cells10102624
crossref_primary_10_3390_biomedicines11020252
crossref_primary_10_1002_cti2_1430
crossref_primary_10_1038_s41467_023_41861_y
crossref_primary_10_3390_nu14081542
crossref_primary_10_1016_j_trsl_2023_08_001
crossref_primary_10_3389_fcell_2021_795251
crossref_primary_10_2478_fco_2024_0007
crossref_primary_10_3390_cancers13205126
crossref_primary_10_1038_s41418_023_01168_3
crossref_primary_10_3390_cancers13194984
crossref_primary_10_2217_epi_2022_0177
crossref_primary_10_3389_fcell_2021_795735
crossref_primary_10_3390_cancers14030546
crossref_primary_10_1002_advs_202501774
crossref_primary_10_1007_s00018_022_04396_x
crossref_primary_10_1158_1078_0432_CCR_22_3089
crossref_primary_10_1080_1120009X_2023_2219920
crossref_primary_10_3390_biomedicines11113058
crossref_primary_10_1007_s12094_024_03478_5
crossref_primary_10_1038_s41598_022_19032_8
crossref_primary_10_3390_cancers14235926
crossref_primary_10_1053_j_gastro_2024_07_001
crossref_primary_10_1186_s10020_023_00757_9
ContentType Journal Article
Copyright Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1053/j.gastro.2021.04.044
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1528-0012
ExternalDocumentID 33915173
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Cancer Research UK
  grantid: 19277
– fundername: Pancreatic Cancer UK
  grantid: FLF2015_06_OXFORD
GroupedDBID ---
--K
.1-
.55
.FO
.GJ
0R~
1B1
1CY
1P~
1~5
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
AAEDT
AAEDW
AAFWJ
AAIKJ
AALRI
AAQFI
AAQOH
AAQQT
AAQXK
AAXUO
ABCQX
ABDPE
ABJNI
ABLJU
ABMAC
ABOCM
ABWVN
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
AENEX
AEVXI
AFCTW
AFFNX
AFHKK
AFJKZ
AFRHN
AFTJW
AGCQF
AGHFR
AGQPQ
AI.
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ASPBG
AVWKF
AZFZN
BELOY
BR6
C5W
CAG
CGR
COF
CS3
CUY
CVF
DU5
EBS
ECM
EFJIC
EFKBS
EIF
EJD
F5P
FD8
FDB
FEDTE
FGOYB
GBLVA
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
M41
MO0
N4W
N9A
NPM
NQ-
O9-
OC.
OHT
ON0
P2P
PC.
QTD
R2-
RIG
ROL
RPZ
SEL
SES
SJN
SSZ
UDS
UGJ
UV1
VH1
WH7
X7M
XH2
Y6R
YQJ
Z5R
ZGI
ZXP
7X8
ID FETCH-LOGICAL-c527t-df9f10f48c65e84af85cf06c9695cb40563b05a983009259c990c77c24b3940d2
IEDL.DBID 7X8
ISICitedReferencesCount 37
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000683663100038&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1528-0012
IngestDate Sun Sep 28 06:15:04 EDT 2025
Mon Jul 21 06:00:11 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Epigenetics
GATA6
TET2
SMAD4
Pancreatic Cancer
Language English
License Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c527t-df9f10f48c65e84af85cf06c9695cb40563b05a983009259c990c77c24b3940d2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://www.gastrojournal.org/article/S001650852100682X/pdf
PMID 33915173
PQID 2520872342
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2520872342
pubmed_primary_33915173
PublicationCentury 2000
PublicationDate 2021-08-00
20210801
PublicationDateYYYYMMDD 2021-08-01
PublicationDate_xml – month: 08
  year: 2021
  text: 2021-08-00
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Gastroenterology (New York, N.Y. 1943)
PublicationTitleAlternate Gastroenterology
PublicationYear 2021
SSID ssj0009381
Score 2.5234916
Snippet Pancreatic ductal adenocarcinoma (PDAC) is characterized by advanced disease stage at presentation, aggressive disease biology, and resistance to therapy,...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 653
SubjectTerms 5-Methylcytosine - analogs & derivatives
5-Methylcytosine - metabolism
Animals
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Ascorbic Acid - pharmacology
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Carcinoma, Pancreatic Ductal - drug therapy
Carcinoma, Pancreatic Ductal - enzymology
Carcinoma, Pancreatic Ductal - genetics
Carcinoma, Pancreatic Ductal - pathology
Cell Differentiation
Cell Line, Tumor
Dioxygenases - genetics
Dioxygenases - metabolism
DNA Methylation - drug effects
DNA-Binding Proteins - genetics
DNA-Binding Proteins - metabolism
Epigenesis, Genetic - drug effects
Epigenome
Epigenomics
GATA6 Transcription Factor - genetics
GATA6 Transcription Factor - metabolism
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Metformin - pharmacology
Mice
Mice, Nude
Mice, Transgenic
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - enzymology
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - pathology
Retrospective Studies
Smad4 Protein - genetics
Smad4 Protein - metabolism
Transcription, Genetic - drug effects
Transcriptome
Wnt Signaling Pathway - genetics
Xenograft Model Antitumor Assays
Title TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes
URI https://www.ncbi.nlm.nih.gov/pubmed/33915173
https://www.proquest.com/docview/2520872342
Volume 161
WOSCitedRecordID wos000683663100038&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvAam-wj2Zyk2FYvLT1U6K1sN7s-sElt2oL_3pkkpSdB8JJLyCbsTma-eX1DyB14PXachIGH1s8TGtwdbYXvGZY4ANhKK6uLYRNRr6eGw7hfBdzyqqxypRMLRZ1kBmPkDSaZryLGBXuYfnk4NQqzq9UIjU1S4wBlUKqj4ZotPOaq5EtFFmbQxKvWOckbH_evOp_PsP2PBQXZqRC_g8zC2HT2__uZB2Svgpm0WcrFIdmw6RHZ6VaJ9GOyHLQHjLZmSDpL5dvEUGzaATNGM0efmoNmSHWa0PYUyTrLPsfPb9qyDqvkaR9EpQCbhrYWZo4vAvUFVnEGq2cTTQsLuNJHcBvUE8Z68xPy0mkPHp-9agSDZySL5l7iYhf4TigTSquEdkoa54cmDmNpxgD2Qj72pY4VR_ImGRswbiaKDBNjHLmesFOylWapPSfUIhmaBZdYwnp-4JRwPDBSR9gIJiWrk9vVjo5AxDFvoVObLfLRek_r5Kw8ltG05OIYcSS4DyJ-8YenL8kunnZZvndFag5-cHtNts1y_p7PbgrZgWuv3_0BulzNLA
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=TET2+Drives+5hmc+Marking+of+GATA6+and+Epigenetically+Defines+Pancreatic+Ductal+Adenocarcinoma+Transcriptional+Subtypes&rft.jtitle=Gastroenterology+%28New+York%2C+N.Y.+1943%29&rft.au=Eyres%2C+Michael&rft.au=Lanfredini%2C+Simone&rft.au=Xu%2C+Haonan&rft.au=Burns%2C+Adam&rft.date=2021-08-01&rft.issn=1528-0012&rft.eissn=1528-0012&rft.volume=161&rft.issue=2&rft.spage=653&rft_id=info:doi/10.1053%2Fj.gastro.2021.04.044&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0012&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0012&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0012&client=summon